Our Pipeline
We are programming biology to create optimal therapeutics for the greatest impact on human health.
| Program | Indication | Target | Modality | Phase | Collaborations | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | |||||||||
| Immunology & Inflammation | ||||||||||||
| GB-0895 | Severe Asthma | TSLP | Antibody |
Phase Phase 3 |
||||||||
| GB-0895 | TSLP |
Modality: monoclonal antibody How this investigational therapy could help: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. GB-0895 is an investigational antibody that binds and neutralizes TSLP to help reduce downstream inflammatory signaling in severe asthma. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. GB-0895 is currently being evaluated in Phase 3 clinical studies. |
||||||||||
| COPD | TSLP | Antibody |
Phase Phase 1 |
|||||||||
| GB-0895 | TSLP |
Modality: monoclonal antibody How this investigational therapy could help: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that contributes to airway inflammation and disease progression in COPD. GB-0895 is an investigational antibody designed to bind and neutralize TSLP, with the goal of reducing downstream inflammatory signaling in chronic airway disease. GB-0895 has been engineered for an extended half-life and is being evaluated in a Phase 1 clinical study in COPD to assess safety, pharmacokinetics, and pharmacodynamic activity. |
||||||||||
| Oncology | ||||||||||||
| GB-4362 | Various in combo with MMAE ADCs | Free MMAE | Antibody |
Phase Phase 1 |
||||||||
| GB-4362 | TSLP |
Modality: monoclonal antibody How this investigational therapy could help: GB-4362 is a monoclonal antibody designed to selectively bind free monomethyl auristatin E (MMAE). Free MMAE is associated with systemic toxicities when released from MMAE-based antibody-drug conjugates. GB-4362 is designed to reduce circulating free MMAE without interacting with intact ADCs. |
||||||||||
| GB-5267 | Metastatic Ovarian Cancer | MUC16 | Armored CAR T |
Phase Phase 1 |
Collaborations 
50/50
|
|||||||
| GB-5267 | Metastatic Ovarian Cancer |
Modality: CAR T-cell therapy How this investigational therapy could help: GB-5267 is an investigational IL-18-armored CAR T-cell therapy that targets MUC16, a cell-surface antigen highly expressed in ovarian cancer. It is designed to redirect a patient’s own T cells to recognize and kill MUC16-expressing tumor cells and enhance T-cell activation, proliferation, and persistence within the tumor microenvironment. GB-5267 is currently being evaluated in a Phase 1 clinical trial in patients with platinum-resistant ovarian cancer. |
||||||||||
Beyond the Clinical Stage Pipeline.
Multiple Other Innovative Preclinical Programs:
Leveraging The Generate Platform™ and its modular capabilities, we are advancing multiple innovative preclinical programs designed with differentiated characteristics beyond the reach of traditional technologies, including next-generation ADCs.
Platform Collaborations:
Six confidential collaboration programs, first announced in January 2022.
Multiple confidential collaboration programs, first announced in September 2024.
Two initial confidential collaboration programs, with an option to add a third, first announced in October 2026.
Policy on Expanded Access (EA) to Investigational Drugs
Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.